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We report for the first time that morphine-6-glucuronide, a highly
analgesicmorphine-derivedmolecule, ispresent inadrenalchromaffin
granules and secreted from chromaffin cells upon stimulation. We
also demonstrate that phosphatidylethanolamine-binding protein
(alternatively namedRaf-1 kinase inhibitor protein orRKIP) acts as an
endogenous morphine-6-glucuronide-binding protein. An UDP-
glucuronosyltransferase 2B-like enzyme, described to transform
morphine into morphine-6-glucuronide, has been immunode-
tected in the chromaffin granule matrix, and morphine-6-glucuro-
nide de novo synthesis has been characterized, demonstrating the
possible involvement of intragranular UDP-glucuronosyltrans-
ferase 2B-like enzyme in morphine-6-glucuronide metabolism.
Once secreted into the circulation, morphine-6-glucuronide may
mediate several systemic actions (e.g. on immune cells) based on its
affinity for -opioid receptors. These activities could be facilitated
by phosphatidylethanolamine-binding protein (PEBP), acting as a
molecular shield and preventing morphine-6-glucuronide from
rapid clearance. Taken together, our data represent an important
observation on the role of morphine-6-glucuronide as a new endo-
crine factor.
For 20 years, cerebral endogenous morphine has been isolated and
characterized, and its structure has been shown to be identical to mor-
phine from poppy (1, 2). In the 1990s, few groups succeeded in charac-
terizing endogenous morphine from the organs and fluids of verte-
brates, including bovine brain and adrenal gland, rat heart and adrenal
gland, and human heart and urine (for review, Refs. 1–3); invertebrates
(4–6); and parasites (7, 8). In mammals, the endogenous morphine
synthetic pathway is associated with the dopamine and catecholamine
biosynthetic pathway (for review, see Refs. 1, 3, and 9). Very recently,
several crucial steps were reached when Zenk and co-workers (10, 11)
demonstrated that morphine can be formed using a multistep biosyn-
thetic route, and Zhu et al. (12) showed that human primary polymor-
phonuclear cells are able to synthesize morphine. These authors have
shown morphine de novo synthesis in human and animal primary and
cancer cell cultures.
Chromaffin cells are neuroendocrine cells originating from the neu-
ral crest and are the predominant cell type in the adrenal medulla (for
review, see Ref. 13). These cells possess the catecholamine biosynthetic
pathway, leading to dopamine and adrenaline/noradrenaline synthesis
(13). Chromaffin secretory granules contain a complex mixture of pep-
tides and proteins that are co-released with catecholamines into the
circulation in response to splanchnic nerve stimulation (13). Based on
themorphine biosynthetic pathway and on the presence ofmorphine in
bovine and rat adrenal glands (14, 15), rat pheochromocytoma PC-12
cells (10, 16), and eel chromaffin cells (17), we hypothesized that mam-
malian chromaffin cells might have the capacity to synthesizemorphine
and that their secretory granules could potentially release this alkaloid
into the blood.
Severalmolecular blood transporters of clinically administratedmor-
phine have been identified (e.g. serum albumin and -globulin (18) and
1-acid glycoprotein (19)). In addition, it has been reported that the
phosphatidylethanolamine-binding protein (PEBP)2 (20), alternatively
named Raf-1 kinase inhibitor protein (RKIP) (21), is also able to bind
morphine (22).We have reported recently that PEBP is present in secre-
tory granules as well as in the exocytotic medium of stimulated bovine
primary cultured chromaffin cells and in bovine serum (23).
Exogenously administeredmorphine is catabolized in the liver by the
UDP-glucuronosyltransferase (UGT) 2B enzyme family (24), leading to
the formation of morphine-3-glucuronide (M3G) andmorphine-6-glu-
curonide (M6G). M3G is totally inactive, whereas M6G appears to dis-
play stronger analgesic activity than morphine (50–600 times depend-
ing on the animal model) (25) and exhibits a much longer half-life (26).
Using immunocytochemical, biochemical, and proteomic strategies,
we reveal in this study that bovine chromaffin cell secretory granules
store the PEBPM6G complex. We show that M6G is secreted from
bovine chromaffin cells upon nicotinic stimulation. Co-immunopre-
cipitation and affinity chromatography experiments also revealed the
interaction between the alkaloid carrier (i.e. PEBP) and a UGT2B-like
enzyme necessary for the conversion of morphine into M6G. Finally,
M6G de novo synthesis was demonstrated using the UGT2B-like
enzyme present in chromaffin granules.
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MATERIALS ANDMETHODS
Immunocytochemistry and Confocal Microscopy Analysis—Bovine
primary chromaffin cells cultured and fixed as described previously (23)
were incubated for 2 h at 37 °C with a rabbit anti-bovine chromogranin
A (CGA)-(124–143) polyclonal antibody (1:200 dilution) (25) and a
commercial sheep polyclonal antibody against morphine-like com-
pounds (i.e. morphine, M3G, and M6G, with minimal cross-reactivity
to codeine as declared by the supplying company; 1:1000 dilution; Bio-
genesis, Bournemouth, UK) (8) in NaCl/Pi buffer (0.9% (w/v) NaCl and
25 mM sodium phosphate, pH 7.5) containing 5% bovine serum albu-
min. Cells were then washed (6 5 min) with NaCl/Pi buffer and incu-
bated with secondary antibodies (Cy5-conjugated donkey anti-rabbit
IgG at 1:2000 dilution andAlexa 488-conjugated donkey anti-sheep IgG
at 1:2000 dilution; Molecular Probes, Eugene, OR) in NaCl/Pi buffer
containing 5% bovine serum albumin for 45 min at 37 °C.
UGT2B was immunodetected using a commercial goat polyclonal
antibody against the human UGT2B family (1:500 dilution; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) and Alexa 488-conjugated donkey
antibodies (1:2000 dilution). CGA was detected with rabbit anti-bovine
CGA-(124–143) polyclonal antibody (1:200 dilution; see above) and
Cy5-conjugated donkey anti-rabbit IgG (1:2000 dilution). All glass cov-
erslips were mounted on a glass slide with a drop of Mowiol 4-88.
Various controls were carried out to assess antibody specificity: (i)
cells without antibody, (ii) secondary antibody incubated alone; and
(iii) primary antibody incubated with the respective antigen prior to
immunolabeling. Anti-UGT2B antibodywas blockedwith the commer-
cial peptide (12 h, 4 °C, 1:5 (w/w) ratio; Santa Cruz Biotechnology, Inc.),
and anti-morphine antibody withM6G (12 h, 4 °C, 1:50 mol/mol ratio).
Immunofluorescence staining was monitored with a Zeiss LSM 510
laser scanning microscope equipped with a Planapo oil immersion
objective (63, numerical aperture of 1.4) (23). Co-localization with
CGA was quantified using Zeiss CLSM Version 2.8 software.
Isolation of Chromaffin Cell Subcellular Fractions—The chromaffin
cell plasma membrane, cytoplasm, intragranular matrix, and granule
membrane were prepared as described by Smith and Winkler (27) and
modified by us (23, 28). After protein quantification using the Bradford
technique, the purity of subcellular fractions was assayed as described
previously using subcellular markers (23). The total microsomal frac-
tion was purified according to Levesque et al. (29).
Isolation of Proteins Exocytotically Released from Stimulated Chro-
maffin Cells—Chromaffin cells (2.5  106) cultured for 3 days were
washed (4 5 min) with 10 ml of Locke’s solution at 37 °C to get rid of
the culture medium and floating dead cells. Cells were subsequently
stimulated for 10 min with 10 M nicotine in Locke’s solution as
described previously (28).
The extracellular medium of unstimulated cells and Locke’s solution
were treatedas controls. Secretedmediumandcontrolswerecentrifugedat
800  g for 10 min at 4 °C and filtered with a 0.22-m syringe filter to
remove cells that might be present in secretions. Samples were acidified
up to 0.1% trifluoroacetic acid (TFA) to prevent degradation (23).
Purification of Alkaloids by RP-HPLC—Subcellular fractions (1 ml of
the corresponding sucrose gradient fraction) were deproteinized and
prepared as described previously (16). Alkaloids were purified using an
A¨KTA purifier HPLC system (Amersham Biosciences AB, Uppsala,
Sweden) and a Nucleosil RP300–5C18 column (4  250 mm, 5-m
particle size, 300-Å porosity; Macherey-Nagel, Hoerdt, France) as
described (23). Gradients are indicated on chromatograms. Buffer A
(TFA 0.1% (v/v) in water) and buffer B (acetonitrile 70%, TFA 0.1% in
water (v/v)) were used.
Mass Spectral Analysis—Mass spectrometry (MS) and tandem MS
(MS/MS) analyses were performed by electrospray MS on a Q-TOF II
(Micromass Ltd., Manchester, UK) in positive mode. Scanning was
done from 50 to 700 m/z in 1 s, and calibration was performed using
0.1% phosphoric acid in 50:50 water/acetonitrile. MS andMS/MS anal-
ysiswere done by nanospray offline usingNanoES spray capillaries (Pro-
tana, Odense, Denmark). For MS/MS experiments, argon grade 5.5 gas
was used for the collision gas, and the collision energy was set to 10–30
eV. MS/MS spectra were acquired using the selection of the precursor
ion by the quadrupole, and fragments were analyzed by time of flight.
The absence of M6G prior to sample application was systematically
controlled using the MS and MS/MS modes.
Affinity Chromatography—Purified anti-bovine PEBP-(1–11) anti-
body (3 mg prepared as described (30)) or commercial anti-human
UGT2B antibody (200g) was coupled to aHiTrapNHS-activated high
performance 1-ml column (Amersham Biosciences) according to the
manufacturer’s instructions. The antibody-coupled column was first
washed with 5 volumes of buffer A (75 mM Tris-HCl, pH 8.0). Samples
(i.e. cytoplasm, microsomes, lysosomes, mitochondria, and intragranu-
lar matrix) resuspended in buffer A (2 mg in a 1-ml final volume) were
loaded onto the column and allowed to stand for 10 min at room tem-
perature. The column was then washed with 10 volumes of buffer A
prior to elution performed with 1 ml of buffer B (150 mMNaCl and 100
mM glycine, pH 3.0). The eluate was immediately neutralized with 20l
of buffer C (1.5 M Tris-HCl, pH 8.0) prior to RP-HPLC analysis or
desalting.
Co-immunoprecipitation Assays—500 g of proteins isolated from
the chromaffin granulematrix was treated as described previously using
anti-human UGT2B antibody (31). Immunoprecipitates were analyzed
by SDS-PAGE andWestern blotting using rabbit anti-bovine PEBP-(1–
11) polyclonal antibody (1:2000 dilution). A semiquantitative approach
with different amounts of the granule matrix protein was used to quan-
tify the amount of PEBP bound to the UGT2B-like enzyme.
Gel Electrophoresis andWestern Blot Analysis—For one-dimensional
electrophoresis analysis, proteins were separated on SDS-polyacryl-
amide containing 10 or 12% acrylamide and electrotransferred as
described (23). For two-dimensional gel electrophoresis analysis, iso-
electric focusing was performed using the PROTEAN IEFTM cell
isoelectric focusing system (Bio-Rad, Marnes-La-Coquette, France)
equipped with dry polyacrylamide gel strips (11-cm immobilized pH
gradient strips) using a pH 4–7 gradient (32). Proteins were immuno-
detected with goat polyclonal antibodies raised against the human
UGT2B family (60 kDa, 1:500 dilution) and immunorevealed with
horseradish peroxidase-conjugated anti-goat antisera. Control experi-
ments using the antibodies were performed as described above. For
silver staining, the gel was incubated in ethanol/acetic acid/water solu-
tion (40:10:50%) and treated using a Dodeca silver stain kit (Bio-Rad)
according to the manufacturer’s instructions.
Tryptic Digestion andMass Spectrometry—Silver-stained bands were
excised, washed with 100 l of 25 mM NH4HCO3, dehydrated twice
with 100l of acetonitrile, and driedwith a SpeedVac evaporator before
reduction (10mMdithiothreitol in 25mMNH4HCO3) and alkylation (55
mM iodoacetamide in 25 mMNH4HCO3) (33). For tryptic digestion, gel
pieces were resuspended in 3 gel volumes of trypsin (12.5 ng/l) freshly
diluted in 25 mM NH4HCO3 and incubated overnight at 35 °C. The
digested peptides were then extracted from the gel in buffer containing
25% H2O, 70% acetonitrile, and 5% formic acid and analyzed by matrix-
assisted laser desorption ionization time-of-flight MS and liquid chro-
matography/MS/MS. For nano-HPLC, a CapLC system (Micromass
Ltd., Manchester, UK) was used. Samples were concentrated on a pre-
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column, and peptides were separated on a column (75 m, inner diam-
eter  15 cm) packed with C18 PepMap (3 m, 100 Å; LC Packings).
The MS and MS/MS analyses were performed with a Q-Tof II hybrid
quadrupole time-of-flight (Q-TOF) mass spectrometer (Micromass
Ltd.). Data analysis was performed with Global Server software (Micro-
mass Ltd.) and Mascote (Matrix Science Ltd., London, UK) against the
NCBI Database.
M6GdeNovo Synthesis—UGT2Bwas purified by affinity chromatog-
raphy on an A¨KTA purifier HPLC System. The eluted material was
desalted on a Sep-Pak cartridge and analyzed byWestern blotting using
anti-UGT2B antibody to confirm the presence of UGT2B-like material.
The eluted fraction was also submitted to gel migration, followed by
silver staining. Silver-stained bands were excised and treated as
described above.
The affinity-purified UGT2B-like enzyme was dried and incubated
for 3 h at 37 °C in a reaction volume of 100 l (100 MUDP-glucuronic
acid, 2mM saccharolactone, 0.9Mmorphine, and 50mMTris-HCl, pH
5.5). The resulting sample was deproteinized and desalted prior to
Q-TOF-MS/MS analysis to examine the presence of M6G. Controls
experiments were performed with the boiled affinity column eluate, the
reaction buffer alone, and morphine used for the assay.
ProteinDeglycosylation—The intragranularUGT2B-like enzymewas
deglycosylated using an enzymatic protein deglycosylation kit (Sigma)
in presence of Triton X-100. Total deglycosylation was carried on using
peptide: N-glycosidase F, O-glycosidase, 2(3,6,8,9)-neuraminidase, 1,4-
galactosidase, and -N-acetylglucosaminidase. The non-deglycosylated
control and the resulting deglycosylated products were loaded onto a
12% SDS-polyacrylamide gel prior to electrotransfer. Deglycosylation
method efficiency was tested using a control glycosylated protein
(fetuin, 10 g) provided in the manufacturer’s kit.
RESULTS
Immunolabeling of Morphine-like Components in Chromaffin Cells—
We extended our previous observations related to the presence of
morphine and its derivatives in adrenal medulla and PC-12 cells
(15, 16) by investigating the subcellular localization of morphine and
its derivatives in chromaffin cells by laser confocal microscopy. Mor-
phine localization was compared with CGA immunoreactivity, a
specific marker of the intragranular matrix of secretory granules
(23). Morphine-like immunolabeling (Fig. 1A, left panel, green) was
observed as bright dots in the cytoplasm, similar to that obtained
with CGA (middle panel, red). The superimposition of the two
labeled materials may suggest a partial intragranular co-localization
in chromaffin granules (Fig. 1, A and B, right panels and arrows).
Control experiments using anti-morphine antibody blocked with
M6G prior to immunocytochemistry experiments or secondary anti-
body alone (Fig. 1C) were carried out to determine the specificity of
labeling.
Characterization of M6G in the Chromaffin Intragranular Matrix—To
clearly demonstrate the presence of M6G in chromaffin granules, bovine
intragranular matrix (33 mg) was isolated and loaded onto an RP-HPLC
column to purify and characterize the alkaloids present. The HPLC gradi-
ent was specifically designed to separate M3G, morphine, M6G, codeine,
andmorphine acetate (500 pmol) (Fig. 2A). Comparison of the chromatog-
raphy profile of the deproteinized intragranular material with the elution
profile of standards indicated the presence of a peak with the same reten-
tion time asM6G. Q-TOF-MS/MS analysis of this peak allowed its unam-
biguous identification as M6G (462.15 Da) according to its fragmentation
profile generating morphine (i.e. 286.13 Da) (Fig. 2B).
FIGURE 1. Immunolabeling of morphine-like components in bovine primary cul-
turedchromaffin cells.A, double immunofluorescenceconfocalmicrographswithanti-
CGA antibody detected with Cy5-conjugated IgG (red) and with antibody against mor-
phine-like molecules revealed with Alexa 488-conjugated IgG (green). Co-localized
immunolabelings (arrows and merged image) are revealed by yellow staining, showing
double-labeled pixels in images of CGA andmorphine labeling recorded simultaneously
in the same optical section. B, higher resolution of immunolabeling in a chromaffin cell
neurite-like extension showing visible individual granules. C, control experiments per-
formed with M6G-adsorbed anti-morphine antibody or with secondary antibody alone.
FIGURE2.HPLCpurificationandMSanalysisofmorphinederivativespresent inbovine
chromaffin granules. A, RP-HPLC purification of standards (M3G,morphine, M6G, codeine
(COD), andmorphine acetate (MA); upper panel) and purification of alkaloid extracted from
bovine soluble intragranular material (lower panel). B, Q-TOF-MS/MS analysis of the HPLC
fractioncorrespondingtoM6Gpresent in the intragranularmaterial (markedwitharrow inA,
lower panel (granulematrix)).mAU, milli-absorbance units; B, buffer B.
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Identification of M6G Secreted from Nicotine-stimulated Cultured
Chromaffin Cells—To characterizeM6G as a secretory product of stim-
ulated chromaffin cells, alkaloid standards (390 pmol) (Fig. 3A, panel 1)
and the extracellular medium were analyzed by RP-HPLC. After stim-
ulation with 10 M nicotine, the secreted material was submitted to 1 N
HCl and chloroform/isopropyl alcohol extractions. Alkaloids present in
the aqueous phase were separated by RP-HPLC on a C18 column (panel
2). A major peak corresponding to the M6G standard was observed. In
extracellular media corresponding to basal secretions, M6G could not
be detected (panel 3), demonstrating the genuine release of M6G upon
nicotine stimulation.
Q-TOF-MS/MS analysis of the peak corresponding to M6G unam-
biguously demonstrated the presence of M6G (462.15 Da) according to
its fragmentation profile wherebymorphine is generated (i.e. 286.13Da)
(Fig. 3B). Similar analysis revealed the absence of M6G in secretions
from unstimulated cells (Fig. 3C).
Evidence for Interaction between PEBP and M6G—We reported
recently that PEBP is present in chromaffin granules and is able to trans-
locate from the cytoplasm to the intragranular space probably via a
granule membrane raft-binding mechanism (23). Based on this prop-
erty, we then examined the capacity of PEBP to bind intragranular mor-
phine-like components by immunoaffinity experiments carried out
using the intragranular matrix, cytoplasm, microsomes, mitochondria,
and lysosomes. Immunoaffinity experiments using the purified anti-
body directed against PEBP-(1–11) were carried out to isolate the puta-
tive intragranular PEBPmorphine-like complex(es). Subcellular frac-
tion extracts (20 mg each) were loaded onto a HiTrap NHS-activated
column coupled with anti-PEBP-(1–11) antibody. The eluted PEBP-
binding molecules were concentrated and then purified by RP-HPLC.
The chromatograms in Fig. 4A represent the elution profile of amixture
of 500 pmol of standards (M3G, morphine, M6G, codeine, and mor-
phine acetate) (panel 1) as well as the purification of immunoaffinity
eluate from 20 mg of intragranular matrix (panel 2), cytoplasm and
microsomes (panel 3), and mitochondria and lysosomes (panels 4 and
5). Peaksmarkedwith arrows on chromatograms representing the affin-
ity elution of the granule matrix, cytoplasm, and microsomes (panels 2
and 3) correspond to the elution time of the M6G standard. Only the
intragranular matrix and, at a lower level, the fraction corresponding to
the cytoplasm and microsomes contain M6G-like molecules, but not
morphine. Q-TOF-MS/MS analysis of the peak corresponding to M6G
of the elution from the granule matrix (panel 2) detected M6G (462.15
Da) and its fragmentation-derived fragment (i.e.morphine, 286.13 Da)
(Fig. 4B). Control experiments using the MS and MS/MS modes with
the elution buffer confirmed that the eluted M6G did not result from
contamination (Fig. 4C).
Subcellular Localization of the UGT2B-like Enzyme in Chromaffin
Cells—Given the presence of M6G in secretory granules, the presence
of an enzyme able to convert morphine toM6G was investigated. It has
been reported that UGT2B family enzymes, which act in this specific
enzymatic reaction, are present in the microsomal fraction of several
organs, including the liver (34). Immunocytochemical experiments
were performed on bovine primary cultured chromaffin cells using anti-
bodies specific to UGT2B enzymes. Confocal laser microscopy revealed
UGT2B immunoreactivity as a dispersed dotted pattern in the cyto-
plasm (Fig. 5A, green), which was found to co-localize partially with
CGA immunoreactivity (red). At a higher magnification, the co-local-
ization of UGT2Bwith the granular marker CGAwas further suggested
particularly in cell extensions (Fig. 5B). UGT2B labeling specificity was
assessed by absorbing antibody with the commercial UGT2B-derived
FIGURE 3. Identification of morphine derivatives secreted from bovine primary chro-
maffincells.A:panel1,RP-HPLCpurificationofalkaloidstandards;panel2, extractedmaterial
present in secreted fluid from primary chromaffin cells in culture stimulated with 10 M
nicotine;panel 3, extractedmaterialpresent in themediumofunstimulatedchromaffincells.
B: Q-TOF-MS/MSanalysis of theHPLC fraction corresponding toM6Gpresent in thematerial
secreted fromchromaffin cells (A,panel 2,arrow).C, Q-TOF-MSanalysis of the corresponding
fraction in the control (basal secretion) (A, panel 3). COD, codeine; MA, morphine acetate;
mAU, milli-absorbance units; B, buffer B.
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peptide or by incubating the secondary fluorescent antibody alone
(Fig. 5C).
To confirmUGT2B-like enzyme localization, SDS-PAGE followed by
Western blot analysis were performed on the intragranular matrix and
microsomal fractions. In this experiment, 10 g of each fraction was
loaded onto a gel, and immunodetection was carried on with anti-
UGT2B antibody. Analysis of the chromaffin granule matrix extract
showed strong labeling as a unique band with an apparent molecular
mass of 55–60 kDa (Fig. 6, lane 1), as expected forUGT2B enzymes (34).
One band with same molecular mass was also detected in the microso-
mal fraction (lane 2). Control experiments using adsorbed anti-UGT2B
antibody and a commercial blocking peptide confirmed antibody spec-
ificity (lane 5).
Immunoprecipitation experiments using anti-UGT2B antibody were
performed to investigate whether a putative complex involving UGT2B
FIGURE 6. Characterization of a UGT2B-like enzyme in the chromaffin granule
matrix byWestern blot analysis. Immunodetection was carried out with the antibody
directed against the UGT2B family. The immunoreactivity at 55–60 kDa corresponds to
UGT2B present in the intragranularmatrix (10g; lane 1) andmicrosomal (10g; lane 2)
proteins. Lane 3, UGT2B-like enzyme purified from3mgof granulematrix extract; lane 4,
total deglycosylation of the purified UGT2B-like enzyme from 3 mg of granule matrix
extract; lane 5, immunodetection performed on intragranular matrix extract using anti-
UGT2B antibody adsorbed with the commercial corresponding blocking peptide.
FIGURE 4. Characterization of morphine derivatives bound to PEBP. A, RP-HPLC of
components elutedby anti-PEBP-(1–11) affinity chromatography: RP-HPLCofM3G,mor-
phine, M6G, codeine (COD), and morphine acetate (MA) standards (panel 1) and of the
affinity eluate from 20 mg of intragranular matrix (panel 2), cytoplasm and microsomes
(panel 3),mitochondria (panel 4), and lysosomes (panel 5).B, Q-TOF-MS/MSanalysisof the
M6G-like fraction from the affinity-eluted intragranular fraction. C, Q-TOF-MS analysis of
the control elution medium.mAU, milli-absorbance units; B, buffer B.
FIGURE 5. ImmunolabelingofUGT2B inbovineprimary cultured chromaffin cells.A,
double immunofluorescence was performed on chromaffin cells with the antibody
against the humanUGT2B family revealedwithAlexa 488-conjugated antibodies (green)
and with anti-CGA-(124–143) antibody detected with Cy5-conjugated IgG (red). Co-lo-
calized immunolabelings are revealed by yellow staining (arrows and merged image),
showingdouble-labeledpixels in the imagesofCGAandUGT2B labeling recorded simul-
taneously in the same optical section. B, shown is the immunolabeling of a chromaffin
cell extension with individual granules. C, the results from control experiments pre-
formedusingUGT2B-adsorbed anti-UGT2B antibody andAlexa 488-conjugated second-
ary antibody alone are shown.
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and PEBP exists in the granule matrix. The data indicated that a com-
plex between the UGT2B-like enzyme and PEBP exists in chromaffin
granules because PEBP was coprecipitated by the antibody directed
against the UGT2B family (data not shown).
Evidence for Glycosylation of the UGT2B-like Enzyme—The UGT2B
family has been described to beN-glycosylated, with glycosylation being
involved in their functional properties (35). Deglycosylation experi-
ments were therefore designed based on the UGT2B-like enzyme pres-
ent in chromaffin granules (Fig. 6, lane 3). Granular extract was treated
with peptide: N-glycosidase F, O-glycosidase, 2(3,6,8,9)-neuramini-
dase, 1,4-galactosidase, and -N-acetylglucosaminidase. Total degly-
cosylation (lane 4) was accompanied by band shift in comparison with
the intragranular material (lanes 1 and 3). A control deglycosylation
assay with fetuin showed effective deglycosylation (data not shown).
The physicochemical characteristics of theUGT2B-like enzymewere
examined by two-dimensional gel electrophoresis using 300g of intra-
granular proteinmaterial. A single broad spot at 55–60 kDa andpI 5was
observed (data not shown), suggesting the structural heterogeneity of
the protein.
Evidence for M6G de Novo Synthesis by the UGT2B-like Enzyme—A
de novo synthesis experiment was designed to determine whether the
UGT2B-like enzyme present in the intragranularmatrix is able to trans-
form morphine into M6G. The UGT2B-like enzyme was first purified
from the intragranular matrix using an anti-UGT2B affinity column.
The resulting eluate was then separated by SDS-PAGE.
Western blot analysis using anti-UGT2B antibody showed an immu-
noreactive band at a molecular mass of 55 kDa (Fig. 7A). This immuno-
reactive band was identical to the one obtained with 5 g of recombi-
nant human UGT2B7 (EC 2.4.1.17; Sigma) (Fig. 7A).
To complete thiswork, a duplicate gel was silver-stained. A band at 55
kDa corresponding to the putative UGT2B-like enzyme as well as other
bands were observed (Fig. 7B). Thus, four additional bands were
FIGURE7.M6Gdenovo synthesis experiment.A,Westernblot analysis of theUGT2B-like enzymeaffinity-purified from4mgof intragranularmatrix andof commercial recombinant
human UGT2B7 (5 g) using anti-UGT2B antibody recognizing the 55-kDa form. B, silver staining of 5 g of intragranular matrix and of the affinity-purified UGT2B-like enzyme
resulting fromUGT2B affinity purification performedwith 4mg of intragranular matrix. Silver-stained bands analyzed byMS after digestion corresponded to PEA or CGA fragments.
C, Q-TOF-MS/MS analysis of de novoM6G synthesis performed on the affinity-purified UGT2B-like enzyme collected from an assaywith 13mg of intragranular proteins.D, Q-TOF-MS
analysis of de novoM6G synthesis using the boiled purified UGT2B-like enzyme showing the absence of M6G and morphine.
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observed at 24, 26, 28, and 60 kDa. Proteomic analysis indicated the
presence in the 24-, 26-, and 28-kDa bands of proenkephalin A (PEA)-
(1–165), PEA-(1–196), and PEA-(1–208) fragments, respectively (36)
(data not shown). The proteomic analysis of the silver-stained 55-kDa
band did not show a similarity to a known protein. The UGT2B enzyme
was not identified because of the absence of bovine UGT2B in protein
data bases and the poor conservation of UGT2B proteins that was
described to be a barrier in the identification of orthologs across species
(for review, see Ref. 37).
M6G de novo synthesis experiments were carried out at the intra-
granular pH of 5.5 (13) using the affinity eluate. After incubation, the
reaction medium was deproteinized and desalted to analyze the pres-
ence of newly synthesized M6G. Q-TOF-MS/MS analysis unambigu-
ously demonstrated the presence ofM6G (462.15 Da) and its character-
istic fragmentation profile (286.13 Da) (Fig. 7C). Q-TOF-MS and
Q-TOF-MS/MS analyses performed on the reaction buffer (UDP-glu-
curonic acid, saccharolactone, and Tris-HCl), the commercial mor-
phine, and the affinity eluate prior to incubation indicated the absence
of M6G (data not shown). An additional control was performed by
incubation with boiled affinity-eluted UGT2B-like enzyme (Fig. 7D). A
464.16-Da component that corresponded to an unidentified molecule
was visible; it did not display the specific M6G fragmentation pattern at
286.13Da corresponding to morphine. This last control demonstrated
that the formation of M6G was totally abolished upon enzyme heat
inactivation.
DISCUSSION
Presence of M6G in Chromaffin Granules—In this work, we have
demonstrated for the first time thatM6G (and notmorphine) is present
in secretory chromaffin granules of bovine adrenal medulla. Because
cytochrome P450 enzymes are localized in the endoplasmic reticulum
membrane of these cells, we surmise thatmorphine is synthesized in the
endoplasmic reticulum/Golgi apparatus by salutaridine synthase (i.e.
cytochrome P450 reductase) (38). Using both immunocytochemical
experiments and biochemical techniques, we have identified M6G
within chromaffin granules. Some diffuse non-granular labeling can be
attributed to morphine-like components present in the endoplasmic
reticulum.
Presence of a PEBPM6G Complex in Chromaffin Granules—The
cytoplasmic PEBP, also named Raf-1 kinase inhibitor protein (20), has
been identified recently in bovine adrenal gland and chromaffin cells
(23, 39). In addition, its presence in the chromaffin intragranularmatrix,
secretionmaterials, and serum has been shown by our group (23). PEBP
has been described to bind various molecules, including indocyanine,
phosphatidylethanolamine, bromosulfophthalein, and hormones such
as estradiol-17 and dehydroepiandrosterone (40). It was thus postu-
lated that PEBP might represent an organic anion transporter with the
same affinity as bovine serum albumin (40). In this study, we have fur-
ther demonstrated that, in the chromaffin intragranular matrix, M6G is
a novel endogenous ligand for PEBP. These binding data are in agree-
mentwith a previous report that described PEBP as amorphine-binding
protein (22). Under our experimental conditions, it is important to
point out that the quantity of M6G could not be determined precisely
because part of the M6G bound to PEBP has been lost probably during
the deproteinization step (i.e. precipitation of part of the PEBPM6G
complex).
Presence of a UGT2B-like Enzyme in Chromaffin Granules—We sur-
mise that, once synthesized, morphine can bind to PEBP in the early
granule stage before its presentation to a conversion enzyme (i.e. the
UGT2B-like enzyme), producing the final active M6G material. Our
data suggest that such a complex, comprising the UGT2B-like enzyme
and PEBP, exists under these experimental conditions.
UGTs represent a superfamily of glycosylated enzymes (35) that
are localized in the endoplasmic reticulum (29, 41) and that catalyze
the glucuronidation reaction of several drugs and steroid hormones.
The glucuronidated products are more polar, less toxic, and easier to
excrete through bile or urine. According to their sequence homologies,
UGTs fall into two classes: UGT1 and UGT2; the later is subdivided in
2A and 2B components (41). To date, the UGT2B subfamily catabolizes
morphine into M3G andM6G (24); UGT2B7 (42, 43) appears to be the
only one in this subfamily able to produce M6G from morphine. Using
immunochemical techniques, we have shown the presence of UGT2B-
like immunoreactivity in chromaffin granules. Our data also demon-
strate the presence of glycosylation on the intragranular UGT2B
enzyme, a post-translational modification reported to occur on other
UGT2B family members (35). The affinity-purified chromaffin granule
UGT2B enzyme has been shown to transform morphine into M6G,
suggesting for the first time its implication in ametabolic process. Up to
now, this property of UGT2B has never been reported.
In our experiments, the proteomic analysis of the silver-stained
55-kDa band (Fig. 7B) did not show similarity to any protein because of
the lack of bovine UGT2B sequences in protein data bases or the pres-
ence of a new UGT2B variant. Indeed, 12 different human UGT2B
genes exist (seven genes and five pseudogenes), and many remnant
genes are also present (for review, see Ref. 37), whereas no bovine
UGT2B gene or protein has been described. UGT2B proteins show 70%
similar sequences, with the higher conservation being present in their
C-terminal domains. This low conservation was described to be a bar-
rier to the identification of orthologs across species (37).
Relevance of the PEBPM6G Complex in the Stress Situation—Be-
cause PEBP andM6G are bound together within the granulematrix and
are co-secreted from bovine chromaffin cells upon stimulation (Fig. 3)
(23), it is likely that the PEBPM6G complex exists after secretion and is
present in the blood. A large variety of proteolytic enzymes are present
in chromaffin secretory granules and act to process precursor proteins
such as PEA and chromogranins/secretogranins (36). In contrast, intra-
granular PEBP is highly resistant to proteolytic degradation (23). PEBP
may also be unaffected by proteolysis in the circulation, thus protecting
M6G from bodily clearance (i.e. excretion through urine and/or bile).
Furthermore, our data suggest that the analgesia observed upon acute
stress (often related to but never totally explained by enkephalin and
corticoid release (44)) might also be due, totally or in part, to M6G
secretion, with PEBP acting as a transporter andmolecular shield. After
secretion,M6Gmaymediate several systemic actions based on its affin-
ity for -opioid receptors present on the cell surface of neurons, neu-
roendocrine cells, the endothelium, and immune cells (2, 45–47).
Interestingly, data from the literature support a separate and select
-opioid receptor for M6G. Thus, using an antisense probe targeting
Gi1 in mammals, Rossi et al. (48, 49) found that both heroin- and
M6G-evoked analgesia (but not that induced by morphine) was
blocked. These results show that heroin, 6-acetylmorphine, fentanyl,
and etonitazine can all produce analgesia through a novel  analgesic
system that is similar to that activated byM6G (48). Antisense mapping
studies on exons 1–3 of MOR-1 (i.e. mu1-opioid receptor-1) in mice
suggested the presence of a novel -receptor subtype responsible for
M6G analgesia thatmay represent a splice variant ofMOR-1 (50, 51). In
addition,we demonstrated previously that, in threemurinemacrophage
cell lines (J774.2, RAW 264.7, and BAC1.2F5), the -opioid receptor
subtype is3 because it binds only opiate alkaloids (i.e.M6G), excluding
M3G or any of the opioid peptides tested (52).
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Clinical Relevance of M6G in Pain Control—It is known that M6G
may have a greater affinity for the 1-opioid receptor (responsible for
analgesia) than for the 2-opioid receptor (responsible for respiratory
depression), suggesting that M6G can offer a benefit as a systemic anal-
gesic (53, 54). M6G is presently under Phase III trial in postoperative
pain (CeNeS Pharmaceuticals, Cambridge, UK), highlighting its biolog-
ical potential.
Interestingly, for 20 years, cellular therapy using adrenal chromaffin
cell transplants has been tested for pain management in both acute and
chronic pain models (55, 56). The resulting antinociceptive effect was
related to the secretion of opioid peptides and catecholamines from the
transplants. Taking into account the present findings and the highly
potent analgesic activity of M6G, we suggest that this alkaloid also par-
ticipates in the analgesia observed in early experiments. Taken together,
the present data may represent important evidence in cell biology and
physiology suggesting a new role of M6G in response to stress.
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